Evidence map›Paper›PMID 36165078›Full record

ReviewCurrent opinion in HIV and AIDS2022

HIV T-cell immunogen design and delivery.

Christian Brander, Dennis Hartigan-O'Connor

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christian BranderIrsicaixa - AIDS Research Institute, Badalona.
Dennis Hartigan-O'ConnorCalifornia National Primate Research Center.

Funding

UC Davis Biostatistics CoreP01AI131568 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STEVENSON, MARIO · 2017 to 2021
$7.1M
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulationR01AI143554 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2018 to 2022
$4.5M
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulationR01AI150554 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2020 to 2023
$3.0M
NIAID NIH HHS P01 AI131568NIAID NIH HHS R01 AI143554NIAID NIH HHS R01 AI150554
6 · The paper itself

Abstract

purpose of the reviewNot all T-cell responses against HIV are created equally and responses of certain epitope specificities have been associated with superior control of infection. These insights have spurred the development of a wide range of immunogen sequences, each with particular advantages and limitations. RECENT

findingsWe review some of the most advanced designs that have reached or are close to reaching human clinical trials, with a special focus on T-cell immunogen developed for therapeutic use. We also touch upon the importance of how immunogens are delivered and point out the lamentable fact that there is essentially no alignment between different designs and vaccine regimens, which is a major hindrance to accelerated advances in the field. SUMMARY: The design of an immunogen able to induce T-cell responses of adequate specificity and functionality is subject of a wide range of preclinical and clinical studies. Few designs have shown promise to date, but emerging data highlight the critical contribution of specificity to effective antiviral activity in vivo .

Indexed as

AIDS VaccinesHIV-1HIV InfectionsAntiviral AgentsEpitopesHumansT-LymphocytesAIDS VaccinesAntiviral AgentsEpitopes

Identifiers

PMID36165078
PMCPMC9530002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.